Replies to post #151808 on Biotech Values

[mcbio]

Against: As an ONXX shareholder, I would not be in favour of an in-licensing. Due to point #3, I think that ARRY is showing their hand and I would use that as leverage. Maybe provide some free drug and help a little bit with trial costs, but not much more.

Appreciate the comments pgs. Regarding point #3, I think ARRY could have some degree of leverage themself as, provided the data agrees, there's the potential for 520+bortezomib combo instead of 520+carfilzomib.